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Abstract 
Background and Aim: Hepatitis C virus (HCV) infection is one of the leading causes of morbidity and mortality 
worldwide. It has been hypothesized that a number of bacteria and viruses might be involved in the pathogenesis of 
cardiovascular disease. The aim of this study was to define the prevalence of HCV in patients with cardiovascular 
disease in comparison with a control group. 
Methods: In this study, 281 individuals including 143 cardiovascular patients and 138 healthy controls were assessed 
for identification of HCV antibodies. The data collection was done between April 2016 and February 2017. The 
prevalence of HCV antibodies was determined by the enzyme-linked immunosorbent assay (ELISA) method.  
Results: There was no HCV infection in both patients with or without cardiovascular disease. There was a significant 
direct correlation between cardiovascular diseases and mean level of FPG (Fasting plasma glucose) (p<0.001). Also 
the Systolic and Diastolic blood pressures were significantly higher in the patients with cardiovascular disease 
(p<0.001 and p=0.005, respectively). 
Conclusion: The results of this study show that no evidence of HCV infection is found among a group of 
cardiovascular patients in the city of Mashhad. 
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Cardiovascular diseases (CVD) are described as a 
range of disorders including the heart or blood 
vessels diseases. CVD may be related to underlying 
factors such as smoking, alcohol consumption, 
diabetes, obesity and high blood cholesterol (1). 
Evidence has emerged indicating that infection is 
also a risk factor of atherosclerosis (2). Many 
studies have shown that a wide range of bacteria 
and viruses can cause cardiovascular disease in 
humans. The most common viral causes of CVD 
and myocarditis are Adenovirus, Cytomegalovirus 
(CMV), Coxsackievirus B, Human parvovirus B19, 
Hepatitis C virus (HCV), and Respiratory syncytial 
virus (RSV) (3-6). Additionally, several studies 
have shown an association between periodontal 
disease such as Porphyromonas gingivalis, 
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Actinobacillus actinomycetemcomitans, 
Treponemadenticola, and Tannerella forsythia and 
CVD (7, 8). 
HCV is a small, enveloped positive-stranded RNA 
virus belonging to the Flaviviridae family and the 
genus Hepacivirus (9). About 2-3% of the world’s 
population is infected with the Hepatitis C virus 
(10, 11). According to the World Health 
Organization's (WHO) report in 2015, only 20% (14 
million) of the 71 million persons living with HCV 
globally were aware of their disease (12, 13). 
HCV can cause both acute and chronic hepatitis 
(the virus leads to chronic hepatitis in up to 60–80% 
of infected people). It is also associated with liver 
steatosis, fibrosis and insulin resistance (14-16). 
In April 2017, WHO declared that the prevalence of 
HCV infection is clearly various in different 
geographic regions (12). Different studies have 
stated that Iran is a country with low-frequency of 
HCV infection (17, 18). The prevalence of HCV 
infection is less than 1% in the general population 
of Iran and it is lower than the neighboring 
countries including Afghanistan (1.1%), Turkey 
(1%-2.1%), Pakistan (4.7%), Iraq (7.1%), and Qatar 
(6.3%) (18). 
Some of the major risk factors for the incidence of 
HCV infection are injecting drug addiction, blood 
product transfusion, organ transplantation, 
hemodialysis, human activities with potential 
exposure to blood, sexual transmission, and vertical 
transmission (17, 19). Up to now, no appropriate 
vaccine or effective post-exposure prophylaxis for 
the disease prevention has been available (20). 
HCV infection is one of the leading causes of death 
worldwide. Cirrhosis and liver failure are the two 
main cause of death in HCV positive patients; 
additionally, some studies demonstrated that CVD 
can be another possible cause of the increased 
mortality rate in these patients (21, 22). Findings 
which are consistent with this are the results of 
clinical studies which have shown that HCV-
infected patients have a higher prevalence of 
metabolic disorders, such as type 2 diabetes 
mellitus, in comparison to non-infected controls 
(23). 
Considering the obtainability of antiviral treatments 
which might impose an extra risk for CVD due to 
their side effects, an updated estimate of the impact 
of HCV infection on CVD risk seems necessary. To 
the best of our knowledge, the prevalence of HCV 
infection among CVD patients has not yet been 
assessed in any study. Hence, we conducted this 
study to define the prevalence of HCV infection 
among a group of individuals with CVD in 
Mashhad city.  
Methods 
In this study, from 2016 to 2017, participants 
(n=281) underwent physical examinations and 
medical interviews. All individuals including those 
with or without CVD were assessed for the 
presence of HCV infection. Diagnosis of CVD 
including stable or unstable angina, myocardial 
infarction or stroke was confirmed by a cardiologist 
and/or a neurologist after physical examination and 
para-clinical evaluation. All the subjects were 
serologically assessed for anti-HCV antibody using 
HCV ELISA kit (Diapro; Italy). Age, gender, job, 
history of smoking, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), fasting glucose and 
lipid levels were measured. Furthermore, data 
related to tobacco and alcohol consumption and 
anthropometric measurements were also collected.  
The process of the study was explained to the 
participants before registration. In addition, each 
item was described individually for the agreement 
to obtain a written consent for those who agreed to 
participate in the study. The study was approved by 
the Ethic Committee of the Mashhad University of 
Medical Sciences. 
Results 
A total of 281 participants (143 CVD patients, and 
138 subjects without any sign or symptoms of 
CVD) aging 36-71 (mean 51.42±6.24) were 
included in our study.  
The demographic characteristics of participants are 
shown in Table 1.  
All serum samples were negative for HCV antibody 
analyzed by ELISA and thus no cases of HCV 
infection was identified in either the case or control 
group. The mean fasting plasma glucose (FPG) 
level in the cardiovascular group was higher than 
the control group which was statistically significant 
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(p<0.001). Also the mean systolic and diastolic 
blood pressures were significantly higher in the 
cardiovascular group (p<0.001 and p=0.005 
respectively) (Table 2). 
 
Table 1. Demographic characteristics of participants 

















































Table 2. Difference in the mean Fasting Plasma Glucose (FPG) and the mean Systolic/diastolic blood pressure in 
patients with and without cardiovascular diseases 
Variable 
Patients with cardiovascular 
disease 
Patients without cardiovascular 
disease 
p-value 
FPG (mg/dL) 124.38±62.70 98.56±55.03 <0.001 
Systolic Blood pressure 
(mm Hg) 
136.27±22.21 124.98±23.39 <0.001 
Diastolic Blood pressure 
(mm Hg) 
84.75±11.15 80.83±12.20 0.005 
 
Discussion 
Numerous studies have shown that the Hepatitis C 
virus (HCV) infection is one of the major causes of 
morbidity and mortality in the world; with a 
mortality rate that is currently higher than HIV 
infections (24-26). Additionally, these studies 
demonstrate the increasing incidence of both liver 
disease and cardiovascular disease (CVD) related 
mortality in HCV patients (27-29).  
The incidence rate of hepatitis C has increased 
worldwide and approximately 2-3% of the world 
population is infected with HCV (12). Recently, the 
relationship between Hepatitis C virus and risk of 
cardiovascular disease has gained interest among 
researchers (5, 29, 30).  
Because HCV infection may interfere with glucose 
and lipid metabolism and eventually lead to the 
development of atherogenic disorders (16), and on 
the other hand, because HCV is reported to prompt 
pro-inflammatory cytokines, such as interleukin 
(IL)-6, tumor necrosis factor (TNF)-α and C-
reactive protein, which can affect the coronary 
arteries resulting in CVD (31), it seems necessary 
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that the risk of CVD in HCV infected individuals be 
estimated. It would also be beneficial to evaluate 
the prevalence of HCV infection among those with 
CVD.  
The current study was implemented to both 
estimate the prevalence of HCV infection in a group 
of individuals diagnosed with CVD and also to 
determine any possible association between HCV 
infection and CVD.  
The result of this study showed that no case of HCV 
infection was present among the study participants; 
either with or without CVD. Therefore, we could 
not assess the association between cardiovascular 
disease and infection with HCV among the studied 
population. This might be due to the relevantly low 
prevalence of HCV infection in Mashhad. In a 
study which was conducted on the general 
population of Mashhad, the seroprevalence of HCV 
was as low as 0.2% and HCV infection prevalence 
was 0.13% (32). 
Liao and colleagues performed a population-based 
cohort to show the relationship between HCV 
infection and risk of stroke. The result of this study 
demonstrated that the risk of stroke in people who 
live with HCV infection was 2.5%, while this risk 
in people without HCV infection was 1.9%. The 
adjusted HR (Hazard ratio) of stroke in HCV 
positive people compared with HCV negative 
people was 1.27 (95% CI 1.14 to 1.41) (30). 
On the other hand, the result of another cohort study 
showed that there was no significant association 
between HCV infection and ischemic heart diseases 
and also the rate of death among ischemic heart 
diseases with anti-HCV seropositive was too low 
(29). The somewhat conflicting results of the 
mentioned studies increase the need for 
implementing larger cohort studies to evaluate the 
more precise relationship between HCV and CVD. 
Results of the current study confirms that HCV 
infection in Iran is mostly diagnosed in individuals 
in high-risk groups such as injecting drug users, 
patients with hemophilia and thalassemia, and 
patients undergoing hemodialysis and it more rarely 
occurs in the general population (33). Thus it is 
difficult to access the difference between the 
prevalence of HCV infection in two subgroups of 
with and without cardiovascular diseases who are 
not in any of the mentioned high risk groups. 
Conclusion 
This study demonstrated that no evidence of HCV 
infection is seen among a group of cardiovascular 
patients in the city of Mashhad and it cannot be 
concluded from this study if there is or not a 
relationship between HCV infection and 
cardiovascular diseases. Our findings can be in 
favor of the concept of the low prevalence of HCV 
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